Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions

Pediatric Pulmonology

Volumn 44, Issue 6, 2009, Pages 568-579

  Bisgaard, Hans ^a   Skoner, David ^b,c   Boza, Maria L ^d   Tozzi, Carol A ^e   Newcomb, Kathleen ^e   Reiss, Theodore F ^e   Knorr, Barbara ^e   Noonan, Gertrude ^e  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b DREXEL UNIVERSITY   (United States)

^c ALLEGHENY GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF CHILE   (Chile)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Asthma; Leukotriene receptor antagonist

Indexed keywords

AMFEBUTAMONE; BECLOMETASONE; BUDESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; MONTELUKAST; NEDOCROMIL; PLACEBO;

ABDOMINAL PAIN; ABNORMAL BEHAVIOR; ADOLESCENT; ALLERGIC RHINITIS; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASTHMA; BILIRUBIN BLOOD LEVEL; CHILD; CLINICAL TRIAL; CONTACT DERMATITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EYE INFECTION; FEVER; HUMAN; HYPERSENSITIVITY; HYPERSOMNIA; INFANT; INFLUENZA; LEUKOCYTE; MAJOR CLINICAL STUDY; MOOD CHANGE; MULTICENTER STUDY; OTITIS MEDIA; PARANASAL SINUS DISEASE; PEAK EXPIRATORY FLOW; PETECHIA; PHARYNGITIS; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; PURULENT RHINITIS; RANDOMIZED CONTROLLED TRIAL; RHINITIS; RHINOPHARYNGITIS; SEIZURE; SIDE EFFECT; SINGLE BLIND PROCEDURE; SINUSITIS; SLEEP DISORDER; SOMNOLENCE; SUICIDAL IDEATION; SUICIDE; SUICIDE ATTEMPT; SUNBURN; THIRST; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VIRUS INFECTION; VOMITING; WHEEZING;

ACETATES; ADOLESCENT; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; QUINOLINES; RHINITIS, ALLERGIC, PERENNIAL;

EID: 67249144738     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.21018     Document Type: Article

References (18)

1. Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N, Michele TM, Reiss TF, Nguyen HH, Bratton DL. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001;108:E48.
2. Nayak A, Langdon RB. Montelukast in the treatment of allergic rhinitis: an evidence-based review. Drugs 2007;67:887-901. (Pubitemid 46607389)
3. Bjermer L. Montelukast in the treatment of asthma as a systemic disease. Expert Rev Clin Immunol 2005;1:325-335.
4. Storms W. Update on montelukast and its role in the treatment of asthma, allergic rhinitis and exercise-induced bronchoconstriction. Expert Opin Pharmacother 2007;8:2173-2187. (Pubitemid 47505591)
5. Storms W, Michele TM, Knorr B, Noonan G, Shapiro G, Zhang J, Shingo S, Reiss TF. Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged ≥6 years. Clin Exp Allergy 2001;31:77-87. (Pubitemid 32158764)
6. Bisgaard H, Garcia MLG, Zielen S, Johnston S, Gilles L, Menten J, Tozzi CA, Polos P. Montelukast reduces viral induced asthma exacerbations in 2 to 5 year old children with intermittent asthma. Am J Respir Crit Care Med 2005;171:315-322. (Pubitemid 40223397)
7. Reiss TF, Knorr B, Malmstrom K, Noonan G, Lu S. Clinical efficacy of montelukast in adults and children. Clin Exp Allergy Rev 2001;1:264-273. (Pubitemid 33754901)
8. Jarvis B, Markham A. Montelukast: a review of its therapeutic potential in persistent asthma. Drugs 2000;59:891-928. (Pubitemid 30232328)
9. Pearlman DS, van Adelsberg J, Philip G, Tilles SA, Busse W, Hendeles L, Loeys T, Dass SB, Reiss TF. Onset and duration of protection against exercise-induced bronchoconstriction by a single oral dose of montelukast. Ann Allergy Asthma Immunol 2006;97:98-104. (Pubitemid 44156345)
10. Kemp JP, Dockhorn RJ, Shapiro GG, Nguyen HH, Reiss TF, Seidenberg BC, Knorr B. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma. J Pediatr 1998;133:424-428. (Pubitemid 28413629)
11. Bisgaard H, for the Study Group on Montelukast and Respiratory Syncytial Virus. A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis. Am J Respir Crit Care Med 2003; 167:379-383.
12. van Adelsberg J, Moy J, Wei LX, Tozzi CA, Knorr B, Reiss T. Safety, tolerability, and exploratory efficacy of montelukast in 6 to 24 month old patients with asthma. Curr Med Res Opin 2005;21:971-979. (Pubitemid 40896245)
13. Pedersen S, Agertoft L, Williams-Herman D, Kuznetsova O, Reiss TF, Knorr B, Dass SB, Wolthers OD. Placebo-controlled study of montelukast and budesonide on short-term growth in prepubertal asthmatic children. Pediatr Pulmonol 2007;42:838-843. (Pubitemid 47580811)
14. Knorr B, Matz J, Bernstein JA, Nguyen H, Seidenberg BC, Reiss TF, Becker A, for the Pediatric Montelukast Study Group. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized double-blind trial. J Am Med Assoc 1998;279:1181-1186.
15. Davies GM, Dasbach EJ, Santanello NC, Knorr BA, Bratton DL. The effect of montelukast versus usual care on health care utilization in children aged 2 to 5 years with asthma. Clin Ther 2004;26:1895-1904. (Pubitemid 40089502)
16. Luz Garcia Garcia M, Wahn U, Gilles L, Swern A, Tozzi CA, Polos P. Montelukast, compared with fluticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: the MOSAIC study. Pediatrics 2005;116:360-369. (Pubitemid 44161461)
17. Becker AB, Kuznetsova O, Vermeulen J, Soto-Quiros ME, Young B, Reiss TF, Dass SB, Knorr BA, for the Montelukast Linear Growth Study Group. Linear growth in prepubertal asthmatic children treated with montelukast, beclomethasone, or placebo: a 56-week randomized double-blind study. Ann Allergy Asthma Immunol 2006;96:800-807.
18. Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research. Guidance for Industry E6-Good Clinical Practice: Consolidated Guidance. Rockville, Maryland, USA: Department of Health and Human Services Food and Drug Administration; 1996. pp. 1-58. http://www.fda.gov/cder/ guidance/index.htm.